SHCC MBCCOP ACCOMPLISHMENTS AND CONTRIBUTIONS
The SHCC Minority-Based Community Clinical Oncology Program, with its novel ancillary programs and dedicated and tireless staff, is an excellent cancer program with national recognition. The program is holistic in approach, and more than 400 women have participated in NCI-approved clinical oncology trials. Our accomplishments and contributions are partly summarized in the lists below:
Scientific Presentations
2007
September 2007 - Poverty predicts aggressive breast cancer phenotype and poor prognosis. ASCO - The Breast Cancer Symposium: Integrating Emerging Science into Clinical Practice, San Francisco, CA.
June 2007 - Absence of racial predilection for aggressive tumor phenotype among low social-economic status women with breast cancer. The 2007 Annual meeting of the American Society of Clinical Oncology, Chicago, IL.
April 2007 - Basal subtype predicts poorer prognosis in younger, but not older, African-American women with breast cancer. The 98th annual meeting of the American Association for Cancer Research, Los Angeles, CA.
2006
December 2006 - p53 gene mutations in African-American women with breast cancer. The 29th Annual San Antonio Breast Cancer Symposium, San Antonio, TX (Submitted).
September 2006 - p53 status is more likely than basal subtype to predict survival in African-American women with breast cancer. AACR Molecular Diagnostics in Cancer Therapeutic Development: Maximizing Opportunities for Individualized Treatment, Chicago, IL.
June 2006 - p53 expression in breast cancer is more likely to predict survival in African-American than Hispanic or white women. The 2006 Annual meeting of the American Society of Clinical Oncology, Atlanta, GA.
April 2006 - Underserved African-American & white women with breast cancer have similar prognostic profiles for estrogen receptor and tumor grade. The 97th annual meeting of the American Association for Cancer Research, Washington, DC.
2005
December 2005 - Low socio-economic status African-American, Hispanic White women with breast cancer demonstrate similar hormone receptor status, tumor grade survival. The 28th Annual San Antonio Breast Cancer Symposium, San Antonio, TX.
April 2005 - HER2/neu overexpression and survival in African-American women with breast cancer. The 96th annual meeting of the American Association for Cancer Research, Anaheim, CA.
April 2005 - Health attitudes, beliefs and habits affect breast cancer screening practice among minority-underserved and low income women. The 96th annual meeting of the American Association for Cancer Research, Anaheim, CA.
2004
December 2004 - Improved yield of perioperative screening for metastases in African-American women with operable breast cancer. The 27th Annual San Antonio Breast Cancer Symposium, San Antonio, TX.
December 2004 - Analysis of hormone receptor function in African-American women with breast cancer. The 27th Annual San Antonio Breast Cancer Symposium, San Antonio, TX.
May 2004 - Delivering the Continuum of Breast Cancer Care to the Underserved: Treatment Issues. 2nd annual Avon Symposium at UCSF Comprehensive Cancer Center, San Francisco, CA.
March 2004 - HER2/neu Status in African-American Women with Breast Cancer. The 95th annual meeting of the American Association for Cancer Research, Orlando, FL.
March 2004 - Early Stage Interval Breast Cancers in African-American Women Demonstrate ER Negative Status & More Aggressive Tumor Biology. The 95th annual meeting of the American Association for Cancer Research, Orlando, FL.
March 2004 - Poor Quality Reporting of Screening Mammography is Associated with Lower Rates of Diagnosis of Early-Stage Breast Cancer in Minority-Underserved Women. The 95th annual meeting of the American Association for Cancer Research, Orlando, FL.
2003
December 2003 - Technical differences contribute to hormone receptor negative status in African-American underserved patients. The 26th Annual San Antonio Breast Cancer Symposium, San Antonio, TX.
December 2003 - ER beta expression parallels ER alpha/ PR expression and is inversely related to EGFR expression in African American women with breast cancer. The 26th Annual San Antonio Breast Cancer Symposium, San Antonio, TX.
November 2003 - The Significance of p53 Immunoreactivity in African-American Patients with Breast Cancer. The Association for Cancer Surgery at the Royal College of Surgeons of England , London , U.K.
October 2003 - Outcome Disparity for Preoperative or Neoadjuvant Chemotherapy in African-American Breast Cancer Patients. AACR Special Conference, Advances in Breast Cancer Research: Genetics, Biology & Clinical Applications, Huntington Beach, CA.
October 2003 - p53 Immunostaining in African-American Breast Cancer Patients is Significantly Associated with Higher Stage & Negative Hormone Receptor Status. AACR Special Conference, Advances in Breast Cancer Research: Genetics, Biology & Clinical Applications, Huntington Beach, CA.
July 2003 - Minority-Underserved Women Treated for Breast Cancer Are at Increased Risk for Poor Mental Health Outcomes. The 94th annual meeting of the American Association for Cancer Research, Washington, DC.
July 2003 - Evaluation of p53 Immunoreactivity in African-American Patients with Breast Cancer. The 94th annual meeting of the American Association for Cancer Research, Washington, DC.
July 2003 - Lower Rates of Diagnosis of Early-Stage Breast Cancer in Minority-Underserved Patients is Associated with Inadequate Screening Practice. The 94th annual meeting of the American Association for Cancer Research, Washington, DC.
May 2003 - Recruitment & Retention of Minority-Underserved Participants to the Star/P2 study is Difficult. The 2003 Annual meeting of the American Society of Clinical Oncology, Chicago, IL.
2002
December 2002 - Fine needle aspirate biopsies of breast lesions are more commonly unsatisfactory and inaccurate when performed by non-surgeons. The 25th Annual San Antonio Breast Cancer Symposium, San Antonio, TX.
October 2002 - Analysis of results for breast cancer screening & early detection in minority-underserved American women. The Fourth Annual Lynn Sage Breast Cancer Symposium, Northwestern University, Chicago, IL.
July 2002 - Black women with breast cancer are more likely to be ER-beta positive. British Cancer Research Meeting 2002, Glasgow, Scotland.
July 2002 - Her2/Neu overexpression in Black women with breast cancer is not associated with negative ER status or higher stage disease. British Cancer Research Meeting 2002, Glasgow, Scotland.
April 2002 - Comparison of prognostic factors for minority-underserved patients with breast cancer. The 93rd annual meeting of the American Association for Cancer Research, San Francisco, CA.
April 2002 - Outcomes for breast cancer screening & early detection in minority-underserved women. The 93rd annual meeting of the American Association for Cancer Research, San Francisco, CA.
April 2002 - Analysis of results for breast cancer screening & early detection in minority-underserved American women. The 11th Congress of the European Society of Surgical Oncology, Lille, France.
April 2002 - A comparison of prognostic factors for minority-underserved American patients with breast cancer. The 11th Congress of the European Society of Surgical Oncology, Lille, France.
April 2002 - A Surgical Perspective of Breast Cancer Screening & Early-Detection in Minority-Underserved Women. Chicago Board of Health, Grand Rounds, Chicago, IL.
February 2002 - Factors influencing post-mastectomy breast reconstruction among minority-underserved patients. The 7th Annual Multidisciplinary Symposium on Breast Disease, Amelia Island, FL.
2001
May 2001 - Clinical trials and tribulations at CCH: implementation of NSABP breast cancer studies. Spring Meeting of the Illinois Surgical Society at CCH, Chicago, IL.
March 2001 - Prognostic Differences for African-American and Other Medically-Underserved Patients with Breast Cancer. The 92nd annual meeting of the American Association for Cancer Research, New Orleans, LA.
Scientific Abstracts & Papers Published
2007
Dookeran KA, Wang Y, Gao X, Ferrer K, Sekosan M, Song S, Radeke EK, Khadire M, McCaskill-Stevens W, Zaren HA. Poverty predicts aggressive breast cancer phenotype and poor prognosis. ASCO - The Breast Cancer Symposium: Integrating Emerging Science into Clinical Practice, San Francisco, CA. Abstract No: 40436.
Dookeran KA, Wang Y, Gao X, Ferrer K, Sekosan M, De La Torre R, Radeke EK, McCaskill-Stevens W, Zaren HA. Absence of racial predilection for aggressive tumor phenotype among low social-economic status women with breast cancer. The 2007 Annual meeting of the American Society of Clinical Oncology, Chicago, IL. Abstract No: 10554.
Dookeran KA, Gao X, Wang Y, Ferrer K, Sekosan M, De La Torre R, Chang, WJ. Mohammed KM, Roman G, Lukaszczyk B, Radeke EK, McCaskill-Stevens W, Zaren HA. Basal subtype predicts poorer prognosis in younger, but not older, African-American women with breast cancer. The 98th annual meeting of the American Association for Cancer Research, Los Angeles, CA. Abstract No: 2510.
2006
Dookeran KA, Gao X, Wang Y, Lukaszczyk B, De La Torre R, Roman G, Ferrer K, Sekosan M, McCaskill-Stevens W, Zaren HA. p53 gene mutations in African-American women with breast cancer. Breast Cancer Research & Treatment 2006 (Submitted).
Dookeran KA, Gao X, Wang Y, Ferrer K, Sekosan M, Lukaszczyk B, Roman G, De La Torre R, Jacobson A, Radeke ER, Mackevicius T, Zaren HA, McCaskill-Stevens W. p53 status is more likely than basal subtype to predict survival in African-American women with breast cancer. Proc. AACR 2006 (In print).
Dookeran KA, Ferrer K, Sekosan M, Gao X, Wang Y, De La Torre R, Lukaszczyk B, Diaz de Leon L, Roman G, Zaren HA. p53 expression in breast cancer is more likely to predict survival in African-American than Hispanic or white women. J. Clin. Oncol. Proc. ASCO 2006;24:#10001.
Dookeran KA, Ferrer K, Sekosan M, Gao X, Wang Y, Diaz de Leon L, Lukaszczyk B, De La Torre R, Roman G, Radeke ER, Muthyala N, Rogowski WA, Zaren HA. Underserved African-American & white women with breast cancer have similar prognostic profiles for estrogen receptor and tumor grade. Proc. AACR 2006;47:#3696.
2005
Dookeran KA, Ferrer K, Sekosan M, Gao X, Sciupokiene E, Wang Y, De La Torre R, Diaz de Leon L, Lukaszczyk B, Zhang S, Song S, Zaren HA. HER2/neu overexpression and survival in African-American women with breast cancer. Proc. AACR 2005;46:114-15,#489.
Dookeran KA, Ferrer K, Sekosan M, Sciupokiene E, Gao X, Wang Y, Lukaszczyk B, Diaz de Leon L, De La Torre R, Zaren HA. p53 expression predicts poorer survival in African-American women with breast cancer. Proc. ASCO 2005;23:870s,#9635.
Dookeran KA, Wang Y, Ferrer K, Sekosan M, Gao X, De La Torre R, Diaz de Leon L, Lukaszczyk B, Roman G, Muthyala N, Rogowski WA, Zaren HA. Low socio-economic status African-American, Hispanic White women with breast cancer demonstrate similar hormone receptor status, tumor grade survival. Breast Cancer Research & Treatment 2005 (In print) 2005;94:S156.
Dookeran KA, Sciupokiene E, Wang Y, Lin J, Mackeviciute-Naujokas A, Whitehall M, Muthyala N, Rogowski WA, Zaren HA. Health attitudes, beliefs and habits affect breast cancer screening practice among minority-underserved and low income women. Proc. AACR 2005;759,#3227.
2004
Dookeran KA, Sciupokiene E, Mackeviciute-Naujokas A, Wang Y, Lin JM, Ferrer K, Sekosan M, Zhang S, Gao X, Zaren HA. Improved yield of perioperative screening for metastases in African-American women with operable breast cancer. Breast Cancer Research & Treatment 2004;88:S97.
Dookeran KA, Sciupokiene E, Mackeviciute-Naujokas A, Elfarra G, Wang Y, Rogowski WA, Muthyala N, Caluser C, Gao X, Ferrer K, Sekosan M, Zaren HA. Poor Quality Reporting of Screening Mammography is Associated with Lower Rates of Diagnosis of Early-Stage Breast Cancer in Minority-Underserved Women. Proc. AACR 2004;45:1213,#5260.
Dookeran KA, Sciupokiene E, Mackeviciute-Naujokas A, Ferrer K, Sekosan M, Gao X, De La Torre R, Diaz de Leon L, Lukaszczyk B, Elfarra G, Wang Y, Rogowski WA, Muthyala N, Caluser C, Zaren HA. Early Stage Interval Breast Cancers in African-American Women Demonstrate ER Negative Status & More Aggressive Tumor Biology. Proc. AACR 2004;45:1213,#5259.
Dookeran KA, Sciupokiene E, Ferrer K, Sekosan M, Mackeviciute-Naujokas A, Gao X, Elfarra G, Wang Y, Rogowski WA, Muthyala N, Zaren HA. HER2/neu Status in African-American Women with Breast Cancer. Proc. AACR 2004;45:1213,#5261.
Dookeran KA, Gao X, Ferrer K, Sciupokiene E, De La Torre R, Diaz de Leon L, Lukaszczyk B, Zhang S, Sekosan M, Zaren HA. Tumor biology in African-American women with breast cancer treated with preoperative chemotherapy: lack of pathologic complete response is related to p53 overexpression. Proc. ASCO 2004;23:95,#880.
Zaren HA, Sciupokiene E, Mackeviciute-Naujokas A, Gao X, Ferrer K, Wang Y, Zhang S, Sekosan M, Dookeran KA. African-American women with breast cancer treated with preoperative chemotherapy have reduced pathologic complete response rates. Proc. ASCO 2004;23:94,#876.
Dookeran KA, Ferrer K, Sekosan M, Gao X, De La Torre R, Diaz de Leon L, Lukaszczyk B, Zhang S, Naujokas A, Sciupokiene E, Zaren HA. Analysis of hormone receptor function in African-American women with breast cancer. Breast Cancer Research & Treatment 2004; 88:S98.
2003
Dookeran KA, Gao X, Ferrer K, Sekosan M, Yang J, Sciupokiene E, Mackeviciute-Naujokas A, Rogowski WA, Muthyala N, Zaren HA. The Significance of p53 Immunoreactivity in African-American Patients with Breast Cancer. Eur. J. Surg. Oncol. 2003;29:829-30.
Dookeran KA, Sciupokiene E, Mackeviciute-Naujokas A, Elfarra G, Rogowski WA, Patel J, Ruestow P, Zaren HA. Minority-Underserved Women Treated for Breast Cancer Are at Increased Risk for Poor Mental Health Outcomes. Proc. AACR 2003:44;185.
Dookeran KA, Gao X, Ferrer K, Sekosan M, Kumar B, Yang J, Sciupokiene E, Mackeviciute-Naujokas A, Rogowski WA, Catchatourian R, Zaren HA. Evaluation of p53 Immunoreactivity in African-American Patients with Breast Cancer. Proc. AACR 2003:44;295.
Dookeran KA, Sciupokiene E, Mackeviciute-Naujokas A, Rogowski WA, Elfarra G, Patel J, Ruestow P, Lavelle MB, Caluser C, Kumar B, Gao X, Yang J, Ferrer K, Sekosan M, Catchatourian R, Zaren HA. Lower Rates of Diagnosis of Early-Stage Breast Cancer in Minority-Underserved Patients is Associated with Inadequate Screening Practice. Proc. AACR 2003 44;295.
Sciupokiene E, Koko I, Dookeran KA, Mackeviciute-Naujokas A, Rogowski WA, Yim B, Catchatourian R, Zaren HA. Factors influencing non-compliance with systemic chemotherapeutic regimens for breast cancer among minority-underserved women. ASCO 2003:22;90.
Zaren HA, Sciupokiene E, Mackeviciute-Naujokas A, Rogowski WA, Elfarra G, Muthyala N, Patel J, Carter M, Ubaka J, Dookeran KA. Recruitment & Retention of Minority-Underserved Participants to the Star/P2 Study is Difficult. ASCO 2003:22;94.
Dookeran KA, Gao X, Ferrer K, Sekosan M, Yang J, Kumar B, Sciupokiene E, Mackeviciute-Naujokas A, Rogowski WA, Zaren HA. HER-2/neu & EGFR Status in African-American Patients with Breast Cancer. Proc. ASCO 2003:22;904.
Zaren HA, Sciupokiene E, Mackeviciute-Naujokas A, Ferrer K, Sekosan M, Caluser C, Koko I, Petrosyan M, Pei K, Muthyala N, Rogowski WA, Dookeran KA. Outcome Disparity for Preoperative or Neoadjuvant Chemotherapy in African-American Breast Cancer Patients. AACR Conference: Advances in Breast Cancer Research Proceedings 2003:B40.
Dookeran KA, Gao X, Ferrer K, Sekosan M, Sciupokiene E, Mackeviciute-Naujokas A, Muthyala N, Rogowski WA, Zaren HA. p53 Immunostaining in African-American Breast Cancer Patients is Significantly Associated with Higher Stage & Negative Hormone Receptor Status. AACR Conference: Advances in Breast Cancer Research Proceedings 2003:A12.
Dookeran KA, Gao X, Yang J, Ferrer K, Sekosan M, Sciupokiene E, Mackeviciute-Naujokas A, Zaren HA. ER beta expression parallels ER alpha/ PR expression and is inversely related to EGFR expression in African American women with breast cancer. Breast Cancer Research & Treatment 2003;82:S63.
Dookeran KA, Gao X, Yang J, Ferrer K, Sekosan M, Sciupokiene E, Mackeviciute-Naujokas A, Rogowski WA, Muthyala N, Koko I, Zaren HA. Technical differences contribute to hormone receptor negative status in African-American underserved patients. Breast Cancer Research & Treatment 2003 (In print) 2003;82:S61-2.
2002
Dookeran KA, Sciupokiene E, Yang J, Elfarra G, Rogowski W, Tran H, Catchatourian R, Zaren HA. Factors influencing postmastectomy breast reconstruction among minority-underserved patients. The Breast 2002; (In publication).
Dookeran KA, Sciupokiene E, Esmailzadeh H, Frush T, Shin F, Rogowski W, Tran H, Yang J, McFarlin M, Reed A, Sekosan M, Catchatourian R, Zaren HA. Comparison of prognostic factors for minority-underserved patients with breast cancer. Proc. AACR 2002;43:238.
Dookeran KA, Sciupokiene E, Esmailzadeh H, Frush T, Shin F, Tran H, Rogowski W, Yang J, Reed A, McFarlin M, Sekosan M, Catchatourian R, Zaren HA. Outcomes for breast cancer screening & early detection in minority-underserved women. Proc. AACR 2002;43:238.
Dookeran KA, Sciupokiene E, Esmailzadeh H, Frush T, Tran H, Rogowski W, Yang J, Sekosan M, Catchatourian R, Zaren HA. Analysis of results for breast cancer screening & early detection in minority-underserved American women. Eur. J. Surg. Oncol. 2002;28:329.
Dookeran KA, Sciupokiene E, Esmailzadeh H, Frush T, Rogowski W, Tran H, Yang J, Sekosan M, Catchatourian R, Zaren HA. A comparison of prognostic factors for minority-underserved American patients with breast cancer. Eur. J. Surg. Oncol. 2002;28:334-5.
Yang J, Dookeran KA, Sekosan M, Sciupokiene E, Rogowski W, Tran H, Catchatourian R, Zaren HA. African-American women with breast cancer are more likely to be ER-beta positive. Proc. ASCO 2002;21:289b.
Dookeran KA, Sciupokiene E, Frush T, Esmailzadeh H, Shin F, Rogowski W, Tran H, Yang J, Sekosan M, Catchatourian R, Zaren HA. HER-2/neu overexpression in African-American women with breast cancer is not associated with negative ER status or higher stage disease. Proc. ASCO 2002;21:296b.
Zaren HA, Sciupokiene E, Frush T, Esmailzadeh H, Shin F, Rogowski W, Tran H, Yang J, Sekosan M, Catchatourian R, Dookeran KA. Minority-underserved women with breast cancer do not receive worse treatment on NCI studies. Proc. ASCO 2002;21:45b.
Dookeran KA, Yang J, Sekosan M, Sciupokiene E, Rogowski W, Tran H, Catchatourian R, Zaren HA. Black women with breast cancer are more likely to be ER-beta positive. British Journal of Cancer 2002;86:S39.
Dookeran KA, Sciupokiene E, Frush T, Esmailzadeh H, Shin F, Rogowski W, Tran H, Yang J, Sekosan M, Catchatourian R, Zaren HA. Her-2/Neu overexpression in Black women with breast cancer is not associated with negative ER status or higher stage disease. British Journal of Cancer 2002;86:S39.
Dookeran KA, Sciupokiene E, Rogowski WA, Elfarrar G, Caluser C, Yang J, Sekosan M, Catchatourian R, Zaren HA. Fine needle aspirate biopsies of breast lesions are more commonly unsatisfactory and inaccurate when performed by non-surgeons. Breast Cancer Research & Treatment 2002;76:S39.
2001
Dookeran KA, Rossi H, Shin F, Tran H, Mullai N, Samuel J, Catchetorian R, Zaren HA. Prognostic differences for African-American and other medically-underserved patients with breast cancer. Proc. AACR 2001;42:890.
Babu L, Agbemadzo B, Mullai N, Samuel J, Dissanayake R, Kio E, Subramaniam D, Dookeran KA, Zaren HA. Incidence of breast cancer in patients less than 40 years old in a minority-based urban hospital. Proc. ASCO 2001;20:36b.
Samuel J, Mullai N, Dissanayake R, Agbemadzo B, Kio E, Subramaniam D, Dookeran KA, Zaren HA. Demographics of breast cancer in a minority-based institution. Proc. ASCO 2001;20:323b.
Dissanayake R, Mullai N, Samuel J, Agbemadzo B, Kio E, Subramaniam D, Dookeran KA, Zaren HA, Ramadurai J. Correlation of estrogen receptor (ER) and HER2/neu (HER2) overexpression in breast cancer patients. Proc. ASCO 2001;20:328b.
Mullai N, Samuel J, Dissanayake R, Agbemadzo B, Subramaniam D, Kio E, Dookeran KA, Zaren HA. Discordance in prognostic factor analysis in breast core biopsies vs. surgical specimens. Proc. ASCO 2001;20:338b.
Dookeran KA, Rossi H, Tran H, Shin F, Catchetourian R, Samuel J, Mullai N, Zaren HA. Differences in breast cancer management outcomes for African-American and other medically-underserved patients. Proc. ASCO 2001;20:216b.
2000
Dookeran KA. Mechanisms of antitumor activity for sustained-release nitric-oxide donor, Nitroprusside in Ethiodol. Proc. AACR 2000;41:280.
